BHC
Bausch Health Companies Inc.
NYSEUSDEQUITY
Healthcare
DELAYED
Buy
+30/100
Last price
6.02
▲ 0.13 (2.21%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
5.89
Day high
6.10
Day low
5.83
Volume
3.05M
Market cap
$2.25B
P/E (TTM)
—
52W range
4.33 – 8.00
Trailing performance
Returnvs SPY
1W
+3.79%
+1.8%
1M
-8.23%
-9.4%
3M
+22.61%
+18.1%
6M
+14.45%
-3.7%
YTD
-13.38%
-27.6%
1Y
-9.88%
-26.3%
3Y
-26.76%
-109.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on BHC open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
41.58M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 19, 26 | LENAR AIMEE J Officer |
SELL | 36.83K | $258.89K | Direct |
| Jun 30, 26 | LEUNG SANDRA Director |
STOCK | 6.84K | $33.75K | Direct |
| Jun 30, 26 | PAULSON JOHN A. Director |
STOCK | 12.68K | $62.50K | Direct |
| May 22, 26 | LEUNG SANDRA Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | KAVANAGH SARAH BALDWIN Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | POWER ROBERT N Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | GARCIA CHRISTIAN A Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | WECHSLER AMY B Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | PAULSON JOHN A. Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | ROBERTS EIRY WYN Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | GOETTLER MICHAEL Director |
STOCK | 45.87K | $0 | Direct |
| May 22, 26 | LEE FRANK DON Director |
STOCK | 45.87K | $0 | Direct |
| May 19, 26 | LEE FRANK DON Director |
SELL | 24.46K | $132.80K | Direct |
| Mar 31, 26 | LEUNG SANDRA Director |
STOCK | 5.95K | $32.11K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
APPIO THOMAS J |
Chief Executive Officer | 3.62M | Stock Award(Grant) |
CARSON SEANA LYNNE |
General Counsel | 616.76K | Sale |
CHARHON JEAN-JACQUES |
Chief Financial Officer | 755.54K | Stock Award(Grant) |
KAVANAGH SARAH BALDWIN |
Director | 282.23K | Stock Award(Grant) |
LENAR AIMEE J |
Officer | 334.85K | Sale |
MILLER STEVEN D |
Director | 239.22K | Stock Award(Grant) |
PAULSON & CO., INC. |
Beneficial Owner of more than 10% of a Class of Security | — | Purchase |
PAULSON JOHN A. |
Director | 73.69M | Stock Award(Grant) |
POWER ROBERT N |
Director | 300.59K | Stock Award(Grant) |
WECHSLER AMY B |
Director | 313.58K | Stock Award(Grant) |
Fundamentals
Market cap$2.25B
Enterprise value$22.17B
Revenue (TTM)$10.85B
Gross profit$7.79B
EBITDA$3.91B
Net income$-1.10B
EPS (TTM)$-2.95
Free cash flow$1.43B
Total cash$1.82B
Total debt$20.78B
Book value / share$-4.74
Shares outstanding373.99M
Float260.57M
Short % of float2.88%
Dividend yield0.00%
Beta (5Y)0.37
Valuation & profitability ratios
Trailing P/E—
Forward P/E1.44
PEG ratio0.01
Price / sales—
Price / book—
EV / revenue2.04
EV / EBITDA5.67
Gross margin71.82%
Operating margin27.17%
Profit margin-10.12%
Return on equity—
Return on assets6.57%
Debt / equity—
Current ratio1.44
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $10.27B | $9.63B | $8.76B | $8.12B | +6.7% |
| Operating revenue | $10.16B | $9.52B | $8.66B | $8.03B | +6.7% |
| Cost of revenue | $3.01B | $2.78B | $2.56B | $2.36B | +8.3% |
| Gross profit | $7.25B | $6.84B | $6.20B | $5.76B | +6.0% |
| Research & development | $629.00M | $616.00M | $604.00M | $529.00M | +2.1% |
| Selling, general & admin | $3.44B | $3.30B | $2.92B | $2.63B | +4.3% |
| Total operating expense | $5.07B | $4.99B | $4.60B | $4.37B | +1.6% |
| Operating income | $2.19B | $1.85B | $1.60B | $1.39B | +17.9% |
| Net interest income | -$1.56B | -$1.35B | -$1.30B | -$1.45B | -14.8% |
| Pre-tax income | $367.00M | $167.00M | -$390.00M | -$129.00M | +119.8% |
| Tax provision | $247.00M | $239.00M | $221.00M | $83.00M | +3.3% |
| Net income | $157.00M | -$46.00M | -$592.00M | -$225.00M | +441.3% |
| Net income to common | $157.00M | -$46.00M | -$592.00M | -$225.00M | +441.3% |
| Basic EPS | 0.42 | -0.13 | -1.62 | -0.62 | +423.1% |
| Diluted EPS | 0.42 | -0.13 | -1.62 | -0.62 | +423.1% |
| EBIT | $1.97B | $1.55B | $938.00M | $1.33B | +26.8% |
| EBITDA | $3.18B | $2.82B | $2.20B | $2.73B | +12.7% |
| Basic shares | 373.81M | 353.85M | 365.43M | 362.90M | +5.6% |
| Diluted shares | 373.81M | 353.85M | 365.43M | 362.90M | +5.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $1.31B | $1.18B | $947.00M | $564.00M | +10.8% |
| Cash & short-term investments | $1.31B | $1.18B | $947.00M | $564.00M | +10.8% |
| Accounts receivable | $2.35B | $2.14B | $2.00B | $1.79B | +9.9% |
| Inventory | $1.63B | $1.59B | $1.54B | $1.09B | +2.1% |
| Total current assets | $6.16B | $5.77B | $5.60B | $4.25B | +6.6% |
| Property, plant & equipment | $2.07B | $1.78B | $1.71B | $1.60B | +16.5% |
| Goodwill & intangibles | $15.91B | $16.64B | $17.64B | $17.35B | -4.4% |
| Total assets | $26.37B | $26.52B | $27.35B | $25.69B | -0.6% |
| Total current liabilities | $4.18B | $6.75B | $4.30B | $3.94B | -38.1% |
| Current debt | $225.00M | $2.67B | $450.00M | $432.00M | -91.6% |
| Long-term debt | $20.59B | $18.94B | $21.94B | $20.33B | +8.7% |
| Total debt | $20.85B | $21.62B | $22.39B | $20.77B | -3.5% |
| Total liabilities | $25.99B | $26.84B | $27.43B | $25.43B | -3.2% |
| Retained earnings | -$9.67B | -$9.82B | -$9.78B | -$9.19B | +1.6% |
| Shareholder equity | -$554.00M | -$1.28B | -$1.02B | -$692.00M | +56.7% |
| Working capital | $1.98B | -$978.00M | $1.29B | $306.00M | +302.1% |
| Net tangible assets | -$16.47B | -$17.92B | -$18.66B | -$18.04B | +8.1% |
| Shares issued | 370.53M | 367.84M | 365.24M | 361.90M | +0.7% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $120.00M | -$72.00M | -$611.00M | -$212.00M | +266.7% |
| Depreciation & amortisation | $1.21B | $1.27B | $1.26B | $1.39B | -4.7% |
| Stock-based compensation | $216.00M | $150.00M | $132.00M | $126.00M | +44.0% |
| Change in working capital | -$219.00M | $7.00M | -$582.00M | -$396.00M | -3,228.6% |
| Operating cash flow | $1.40B | $1.60B | $1.03B | -$728.00M | -12.3% |
| Capital expenditure | -$407.00M | -$340.00M | -$272.00M | -$268.00M | -19.7% |
| Investing cash flow | -$595.00M | -$454.00M | -$2.15B | -$303.00M | -31.1% |
| Financing cash flow | -$742.00M | -$868.00M | $1.48B | -$474.00M | +14.5% |
| Free cash flow | $993.00M | $1.26B | $760.00M | -$996.00M | -21.0% |
| End cash position | $1.32B | $1.20B | $962.00M | $591.00M | +10.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $2.85B | $2.52B | $2.80B | $2.68B | $2.53B | +13.0% |
| Operating revenue | $2.83B | $2.50B | $2.77B | $2.66B | $2.50B | +13.0% |
| Cost of revenue | $772.00M | $738.00M | $798.00M | $750.00M | $764.00M | +4.6% |
| Gross profit | $2.08B | $1.79B | $2.00B | $1.93B | $1.77B | +16.5% |
| Research & development | $173.00M | $163.00M | $51.00M | $247.00M | $159.00M | +6.1% |
| Selling, general & admin | $907.00M | $861.00M | $882.00M | $795.00M | $894.00M | +5.3% |
| Total operating expense | $1.30B | $1.26B | $1.17B | $1.29B | $1.31B | +3.2% |
| Operating income | $775.00M | $521.00M | $829.00M | $636.00M | $457.00M | +48.8% |
| Net interest income | -$385.00M | -$392.00M | -$388.00M | -$397.00M | -$452.00M | +1.8% |
| Pre-tax income | $348.00M | -$1.35B | $56.00M | $218.00M | $140.00M | +125.7% |
| Tax provision | $88.00M | $77.00M | $159.00M | $37.00M | $12.00M | +14.3% |
| Net income | $258.00M | -$1.42B | -$112.00M | $179.00M | $148.00M | +118.1% |
| Net income to common | $258.00M | -$1.42B | -$112.00M | $179.00M | $148.00M | +118.1% |
| Basic EPS | 0.69 | -3.82 | -0.30 | 0.48 | 0.40 | +118.1% |
| Diluted EPS | 0.68 | -3.82 | -0.30 | 0.48 | 0.40 | +117.8% |
| EBIT | $744.00M | -$952.00M | $453.00M | $630.00M | $605.00M | +178.2% |
| EBITDA | $1.02B | -$657.00M | $743.00M | $936.00M | $912.00M | +256.0% |
| Basic shares | 375.00M | 372.80M | 373.33M | 372.92M | 370.90M | +0.6% |
| Diluted shares | 378.10M | 372.80M | 373.33M | 372.92M | 373.10M | +1.4% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $1.82B | $1.30B | $1.31B | $1.31B | $1.73B | +40.5% |
| Cash & short-term investments | $1.82B | $1.30B | $1.31B | $1.31B | $1.73B | +40.5% |
| Accounts receivable | $2.26B | $2.19B | $2.35B | $2.42B | $2.21B | +3.3% |
| Inventory | $1.60B | $1.60B | $1.63B | $1.60B | $1.66B | +0.1% |
| Total current assets | $6.52B | $5.98B | $6.16B | $6.25B | $6.51B | +9.1% |
| Property, plant & equipment | $2.10B | $2.10B | $2.07B | $2.03B | $1.99B | +0.1% |
| Goodwill & intangibles | $13.97B | $14.21B | $15.91B | $16.12B | $16.34B | -1.7% |
| Total assets | $24.79B | $24.50B | $26.37B | $26.82B | $27.27B | +1.2% |
| Total current liabilities | $4.54B | $4.53B | $4.18B | $4.79B | $4.97B | +0.3% |
| Current debt | $866.00M | $889.00M | $225.00M | $579.00M | $879.00M | -2.6% |
| Long-term debt | $19.88B | $19.88B | $20.59B | $20.46B | $20.86B | 0.0% |
| Total debt | $20.78B | $20.80B | $20.85B | $21.04B | $21.74B | -0.1% |
| Total liabilities | $25.60B | $25.58B | $25.99B | $26.47B | $27.12B | +0.1% |
| Retained earnings | -$10.83B | -$11.09B | -$9.67B | -$9.55B | -$9.73B | +2.3% |
| Shareholder equity | -$1.77B | -$2.06B | -$554.00M | -$565.00M | -$764.00M | +14.0% |
| Working capital | $1.98B | $1.45B | $1.98B | $1.46B | $1.54B | +36.6% |
| Net tangible assets | -$15.74B | -$16.27B | -$16.47B | -$16.68B | -$17.11B | +3.2% |
| Shares issued | 373.90M | 373.46M | 370.53M | 370.47M | 369.75M | +0.1% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Net income | $260.00M | -$1.43B | -$103.00M | $181.00M | $128.00M | — | +118.2% |
| Depreciation & amortisation | $281.00M | $295.00M | $290.00M | $306.00M | $307.00M | — | -4.7% |
| Stock-based compensation | $54.00M | $52.00M | $84.00M | $43.00M | $46.00M | — | +3.8% |
| Change in working capital | $17.00M | -$43.00M | -$192.00M | -$53.00M | $91.00M | — | +139.5% |
| Operating cash flow | $670.00M | $230.00M | $495.00M | $405.00M | $289.00M | — | +191.3% |
| Capital expenditure | -$77.00M | -$147.00M | -$92.00M | -$91.00M | -$100.00M | — | +47.6% |
| Investing cash flow | -$93.00M | -$139.00M | -$282.00M | -$83.00M | -$100.00M | — | +33.1% |
| Dividends paid | $0 | $0 | — | $0 | $0 | $0 | — |
| Financing cash flow | -$49.00M | -$100.00M | -$235.00M | -$719.00M | $358.00M | — | +51.0% |
| Free cash flow | $593.00M | $83.00M | $403.00M | $314.00M | $189.00M | — | +614.5% |
| End cash position | $1.84B | $1.31B | $1.32B | $1.34B | $1.74B | — | +40.1% |
Options analytics
Put / call volume
0.39
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
1.00
-83.4% from spot
ATM implied vol
0.0%
Nearest strike to spot
Skew (10% OTM)
-25.0%
Calls bid over puts
Call volume
41
Contracts, this expiry
Put volume
16
Contracts, this expiry
Heaviest call OI
2.00
39 contracts
Heaviest put OI
5.50
0 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | 1.01 | 1.26 | +25.1% |
| Mar 2026 | 0.69 | 0.78 | +12.8% |
| Dec 2025 | 1.26 | 1.10 | -12.9% |
| Sep 2025 | 1.06 | 1.16 | +10.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | 1.22 | 6 | $2.75B | +2.4% |
| Next quarter | 1.30 | 6 | $2.80B | +0.1% |
| Current year | 4.47 | 6 | $10.88B | +6.0% |
| Next year | 4.19 | 6 | $10.89B | +0.0% |
Analyst targets & ownership
Mean target$7.50
High target$9.00
Low target$6.50
Implied upside24.58%
Analyst count5
ConsensusHOLD
Strong buy / Buy0 / 0
Hold7
Sell / Strong sell0 / 0
Held by insiders11.12%
Held by institutions65.07%
Institutions holding313
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
5.79
+3.99% from price
SMA 20
5.80
+3.77% from price
SMA 50
6.15
-2.05% from price
SMA 100
5.57
+8.00% from price
SMA 200
5.77
+4.35% from price
EMA 12
5.85
+2.99% from price
EMA 26
5.91
+1.79% from price
EMA 50
5.89
+2.19% from price
RSI (14)
53.7
Neutral
MACD (12,26,9)
-0.07
Hist 0.03
ATR (14)
0.21
3.48% of price
Realised vol 30D
35.1%
Annualised
Bollinger upper
6.09
20, 2σ
Bollinger lower
5.51
20, 2σ
50 / 200 cross
Golden
6.15 vs 5.77
Trend bias
Above 200
+4.35%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.98
Less volatile than market
Correlation to SPY
0.23
Largely independent
Realised vol 30D
35.1%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-43.9%
Peak to trough
Max drawdown 5Y
-85.1%
Peak to trough
ATR 14
0.21
3.48% of price
Beta (reported)
0.37
5Y monthly, from filing
Short interest
Shares short
8.63M
Prior 8.42M
Change vs prior
+2.5%
Shorts adding
% of float
2.88%
Normal
% of shares out
2.31%
Against total outstanding
Days to cover
3.1
Liquid
Float
260.57M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Apr 27, 26 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Feb 25, 26 | Barclays | MAINTAINED | Equal-Weight | Equal-Weight |
| Jan 7, 26 | Truist Securities | MAINTAINED | Hold | Hold |
| Dec 9, 25 | Barclays | INITIATED | — | Equal-Weight |
| May 2, 25 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Feb 6, 25 | Jefferies | DOWNGRADE | Buy | Hold |
| Jan 30, 25 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Nov 1, 24 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Aug 2, 24 | RBC Capital | MAINTAINED | Sector Perform | Sector Perform |
| Aug 2, 24 | Piper Sandler | DOWNGRADE | Neutral | Underweight |
| Jul 25, 24 | Truist Securities | MAINTAINED | Hold | Hold |
| Jul 10, 24 | Raymond James | INITIATED | — | Market Perform |
Dividends & splits
Forward rate—
Forward yield0.00%
5-year avg yield1.30%
Payout ratio0.00%
Ex-dividend dateNov 10, 2010
Next pay date—
Last split2:1
Split dateOct 16, 2000
SEC filings
Periodic Financial Reports
10-Q · 2026-07-30
Corporate Changes & Voting Matters
8-K · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-07-01
Specialized Disclosure Report filed pursuant to Section 1502 of the Dodd-Frank Wall Street Reform and Consumer Protection Act relating to the use of conflict minerals (Rule 13p-1)
SD · 2026-06-01
Corporate Changes & Voting Matters
8-K · 2026-05-19
Periodic Financial Reports
10-Q · 2026-04-30
Corporate Changes & Voting Matters
8-K · 2026-04-29
Proxy Statements
DEFA14A · 2026-04-08
Headlines
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
CNW Group · 24h ago
Bausch Health to Announce Third Quarter 2026 Results on October 28, 2026
PR Newswire · 24h ago
The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies
Zacks · 2d ago
4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike
Zacks · 5d ago
Consumer Confidence Falls Amid Ongoing Geopolitical Tensions: 4 Picks
Zacks · 7d ago
Zacks Value Investor Highlights: FOXF, BHC and QNST
Zacks · 9d ago
Screening for Hidden Gem Stocks Under $20
Zacks · 13d ago
Best Value Stocks to Buy for September 22nd
Zacks · 15d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.